コンテンツへスキップ
Merck
  • Sodium bicarbonate infusion to reduce cardiac surgery-associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial.

Sodium bicarbonate infusion to reduce cardiac surgery-associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial.

Critical care medicine (2013-05-21)
Shay P McGuinness, Rachael L Parke, Rinaldo Bellomo, Frank M P Van Haren, Michael Bailey
要旨

Cardiac surgery-associated acute kidney injury occurs in up to 50% of patients and is associated with increased mortality and morbidity. This study aimed to discover if perioperative urinary alkalinization with sodium bicarbonate infusion reduces the prevalence of cardiac surgery-associated acute kidney injury. This study was a phase IIb multicenter double-blind randomized controlled trial. This study was conducted in three tertiary hospitals in New Zealand and Australia. A total of 427 patients scheduled to undergo elective cardiac surgery, who were at increased risk of development of cardiac surgery-associated acute kidney injury using recognized risk factors. Patients were randomly allocated to receive either sodium bicarbonate (n = 215) or sodium chloride (n = 212) infusion, commencing at the start of anesthesia, in a dose of 0.5 mEq/kg/hr for the first hour and then 0.2 mmol/kg/hr for 23 hours. The primary outcome measure was the number of patients with development of cardiac surgery-associated acute kidney injury, defined as an increase in creatinine greater than 25% or 0.5 mg/dL (44 µmol/L) from baseline to peak value within the first five postoperative days. Significant differences among the groups in both plasma and urinary biochemistry were achieved 6 hours after commencement of the infusion, and these changes persisted for more than 24 hours. A total of 100 out of 215 patients (47% [95% CI, 40%-53%]) in the sodium bicarbonate group and 93 of 212 patients (44% [95% CI, 37%-51%]) in the sodium chloride group with development of acute kidney injury within the first five postoperative days (p = 0.58). There were also no significant differences in ventilation hours, ICU or hospital length of stay, or mortality. Perioperative alkalinization of blood and urine using an infusion of sodium bicarbonate did not result in a decrease in the prevalence of acute kidney injury in patients following cardiac surgery.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
重炭酸ナトリウム, ACS reagent, ≥99.7%
Sigma-Aldrich
重炭酸ナトリウム, powder, BioReagent, for molecular biology, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
重炭酸ナトリウム, ReagentPlus®, ≥99.5%, powder
Sigma-Aldrich
炭酸水素ナトリウム 溶液, solution (7.5%), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
重炭酸ナトリウム, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E500, 99.0-100.5%, powder
Sigma-Aldrich
重炭酸ナトリウム, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99.5%
Sigma-Aldrich
重炭酸ナトリウム, BioXtra, 99.5-100.5%
Sigma-Aldrich
重炭酸ナトリウム, −40-+140 mesh, ≥95%
Sigma-Aldrich
炭酸水素ナトリウム, SAJ first grade, 99.5-100.3%
Supelco
重炭酸ナトリウム濃縮物, 0.1 M NaHCO3 in water, eluent concentrate for IC
Sigma-Aldrich
Sodium bicarbonate-12C, 99.9 atom % 12C
Sigma-Aldrich
重炭酸ナトリウム, tested according to Ph. Eur.
Sigma-Aldrich
重炭酸ナトリウム, JIS special grade, 99.5-100.3%